Celgene Corp. (CELG)

CELG (NASDAQ:Biotechnology) EQUITY
$92.71
pos +0.74
+0.80%
Today's Range: 91.90 - 93.34 | CELG Avg Daily Volume: 6,419,900
Last Update: 08/14/18 - 4:00 PM EDT
Volume: 4,955,453
YTD Performance: -11.87%
Open: $91.94
Previous Close: $91.97
52 Week Range: $74.13 - $147.17
Oustanding Shares: 703,363,000
Market Cap: 64,153,738,281
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 13 14 14 14
Moderate Buy 1 1 1 1
Hold 10 10 12 13
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.88 1.84 1.93 1.96
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 21.16
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
21.16 25.25 20.50
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
8.79% -29.58% -29.42%
GROWTH 12 Mo 3 Yr CAGR
Revenue 17.40 0.70 0.19
Net Income 46.69 0.50 0.14
EPS 46.19 0.50 0.15
Earnings for CELG:
EBITDA 3.65B
Revenue 12.82B
Average Earnings Estimates
Qtr (09/18) Qtr (12/18) FY (12/18) FY (12/19)
Average Estimate $1.99 $2.13 $7.64 $9.47
Number of Analysts 3 3 1 3
High Estimate $2.01 $2.15 $7.64 $9.61
Low Estimate $1.98 $2.12 $7.64 $9.27
Prior Year $1.78 $1.87 $6.84 $7.64
Growth Rate (Year over Year) 11.99% 14.08% 11.70% 23.91%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
Investors might be finally recognizing the hidden value of the firms' drug research and development.
With biotech names getting some attention this morning a quick review looks like a good idea.
Charts suggest Celgene has put in a low for now.
Taking the measure of what's keeping the markets in the dumps.
Here's our new strategy for the shares.

Emboldened By Biotech Names Real Money Pro($)

For the trade, I'm opting to use the iShares Nasdaq Biotechnology ETF.

A Rash of Biotech News Real Money Pro($)

The April Jobs report showed that 164,000 jobs were created last month. This is nearly 30,000 jobs less than the consensus. Unemployment rates tumbles to 3.9%, the first time under the 4% level in almost two decades.
The Chinese have something to lose here, and will not willingly surrender their position of superiority in trade.

Columnist Conversations

View Chart »  View in New Window » BA chart I'm STALKING this one for a buy trigger........
View Chart »  View in New Window »   WEEKLY
BABA is still dancing on key weekly support here.  Wait for a trigger! View Chart »  Vi...
BABA is still dancing on key weekly support here.  Wait for a trigger! View Chart »  Vi...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

COLUMNIST TWEETS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.